CompletedPhase 4

Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

Netherlands84,496 participantsStarted 2008-09

Plain-language summary

The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female adults aged 65 years or older on the day of vaccination and able to fulfill study requirements. Exclusion Criteria: * Previous vaccination with any licensed or experimental pneumococcal vaccine * Residence in a nursing home, long-term care facility, or similar facility * Known hypersensitivity to vaccination * Immune deficiency or suppression

What they're measuring

Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)

Timeframe: Baseline up to occurrence of first episode of VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)

Trial details

NCT IDNCT00744263

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-10

Results submitted2014-10-01

View on ClinicalTrials.gov More Pneumonia, Pneumococcal trials